Ipca Laboratories Limited

NSE IPCALAB.NS

Ipca Laboratories Limited Price to Sales Ratio (P/S) on February 07, 2025: 4.79

Ipca Laboratories Limited Price to Sales Ratio (P/S) is 4.79 on February 07, 2025, a -2.95% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Ipca Laboratories Limited 52-week high Price to Sales Ratio (P/S) is 5.81 on January 07, 2025, which is 21.25% above the current Price to Sales Ratio (P/S).
Ipca Laboratories Limited 52-week low Price to Sales Ratio (P/S) is 3.62 on June 27, 2024, which is -24.38% below the current Price to Sales Ratio (P/S).
Ipca Laboratories Limited average Price to Sales Ratio (P/S) for the last 52 weeks is 4.68.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NSE: IPCALAB.NS

Ipca Laboratories Limited

CEO	Mr. Pranay Premchand Godha
IPO Date	Jan. 1, 1996
Location	India
Headquarters	125, Kandivli Industrial Estate
Employees	17,335
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cosmetics Drugstores & Retail Pharmacies Personal Care

Description

Ipca Laboratories Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, dermatology, diabetology, gastroenterology, haematology, neurology, ophthalmology, rheumatology, and urology, as well as respiratory, psychiatry, probiotics, orthopedics, oral anti diabetes drug, nutraceuticals, NSAIDs, neuropathic pain, malaria, infectious diseases, immunosuppressant, hepatoprotectives, helminthics, fever, and emollients/protectives. It exports its products to approximately 100 countries worldwide. The company was incorporated in 1949 and is based in Mumbai, India.

Key trends

Past 5 years